NCT02546349View on ClinicalTrials.gov

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

PHASE4UnknownINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
COPD
Interventions
DRUG

fluticasone/salmeterol, tiotropium

In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.

Trial Locations (1)

886

Taipei Veterans General Hospital, Taipei

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

NCT02546349 - Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA | Biotech Hunter | Biotech Hunter